PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21805188-5 2012 In vitro, the nanoparticle targeted the nucleolin receptor on a cell and ligand-specific manner and improved cytotoxicity of doxorubicin (used as a model drug) towards breast cancer and endothelial cells by 177- and 162-fold, respectively, relative to the commercially available non-targeted non-pH-sensitive liposomes. Doxorubicin 125-136 nucleolin Homo sapiens 40-49 20510077-0 2010 [Effect of down-regulation of nucleolin on adriamycin-induced apoptosis and inhibition of proliferation in breast cancer cells]. Doxorubicin 43-53 nucleolin Homo sapiens 30-39 34591471-8 2021 Flow cytometry and confocal fluorescence microscopy revealed that DOX/UiO-66-PEG-F3 had stronger accumulation in MDA-MB-231 cells (nucleolin+) compared with DOX/UiO-66-PEG. Doxorubicin 66-69 nucleolin Homo sapiens 131-140 34542145-6 2021 Intracellular uptake and cytotoxicity experiments confirmed that the nanocarrier DNA-BSA1@DOX had accurate targeting and efficient treatment towards cancer cells due to the high affinity and specificity of AS1411 to nucleolin, which is overexpressed in cancer cells. Doxorubicin 90-93 nucleolin Homo sapiens 216-225 35565346-7 2022 A two- to twelve-fold improvement in cytotoxicity, subsequent to internalization into the lung cancer cell lines of doxorubicin-loaded liposomes functionalized by the nucleolin-binding F3 peptide, was correlated with the nucleolin cell surface levels and the corresponding extent of cell binding. Doxorubicin 116-127 nucleolin Homo sapiens 167-176 34207464-0 2021 The Enhanced Efficacy of Intracellular Delivery of Doxorubicin/C6-Ceramide Combination Mediated by the F3 Peptide/Nucleolin System Is Supported by the Downregulation of the PI3K/Akt Pathway. Doxorubicin 51-62 nucleolin Homo sapiens 114-123 35565346-7 2022 A two- to twelve-fold improvement in cytotoxicity, subsequent to internalization into the lung cancer cell lines of doxorubicin-loaded liposomes functionalized by the nucleolin-binding F3 peptide, was correlated with the nucleolin cell surface levels and the corresponding extent of cell binding. Doxorubicin 116-127 nucleolin Homo sapiens 221-230 35425440-4 2022 Cleverly utilizing the DNA tunability, AS1411 aptamer which binds nucleolin, a protein specifically expressed on tumor-associated endothelial cells, was designed with ATP aptamer and its cDNA to load the anticancer drug, doxorubicin (Dox). Doxorubicin 221-232 nucleolin Homo sapiens 66-75 35425440-4 2022 Cleverly utilizing the DNA tunability, AS1411 aptamer which binds nucleolin, a protein specifically expressed on tumor-associated endothelial cells, was designed with ATP aptamer and its cDNA to load the anticancer drug, doxorubicin (Dox). Doxorubicin 234-237 nucleolin Homo sapiens 66-75 33833512-0 2021 Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment. Doxorubicin 75-86 nucleolin Homo sapiens 0-9 33860446-0 2022 Modelling the impact of nucleolin expression level on the activity of F3 peptide-targeted pH-sensitive pegylated liposomes containing doxorubicin. Doxorubicin 134-145 nucleolin Homo sapiens 24-33 33860446-5 2022 Modeling enabled the prediction of nucleolin-mediated total doxorubicin exposure provided by the experimental settings of the assessment of PEGASEMP"s impact on cell death. Doxorubicin 60-71 nucleolin Homo sapiens 35-44 31546295-3 2019 The conjugate had an affinity for nucleolin, with higher uptake and retention into the cancer cells than those of DOX. Doxorubicin 114-117 nucleolin Homo sapiens 34-43 32658190-3 2020 AS1411 is specifically bonded with targeted nucleolin receptors on cancer cells so that DOX targets cancer cells instead of healthy cells. Doxorubicin 88-91 nucleolin Homo sapiens 44-53 32223128-3 2020 Briefly, mesoporous silica materials (MSN) loaded with doxorubicin (DOX) and phorbol 12-myristate 13-acetate (PMA) was used as drug carrier and could be specifically opened by nucleolin in HeLa cell. Doxorubicin 55-66 nucleolin Homo sapiens 176-185 32223128-3 2020 Briefly, mesoporous silica materials (MSN) loaded with doxorubicin (DOX) and phorbol 12-myristate 13-acetate (PMA) was used as drug carrier and could be specifically opened by nucleolin in HeLa cell. Doxorubicin 68-71 nucleolin Homo sapiens 176-185 31127617-0 2019 Effect of nucleolin on adriamycin resistance via the regulation of B-cell lymphoma 2 expression in Burkitt"s lymphoma cells. Doxorubicin 23-33 nucleolin Homo sapiens 10-19 31127617-6 2019 Adriamycin (ADM) IC50 levels for CA46-NCL-overexpressed (OE), CA46-NCL-OE control (OEC), CA46-NCL-knockdown (KD), and CA46-NCL-KD control (KDC) cells were 0.68 +- 0.06 mug/ml, 0.68 +- 0.06 mug/ml, 0.68 +- 0.06 mug/ml, and 0.30 +- 0.04 mug/ml, respectively. Doxorubicin 0-10 nucleolin Homo sapiens 38-41 31127617-6 2019 Adriamycin (ADM) IC50 levels for CA46-NCL-overexpressed (OE), CA46-NCL-OE control (OEC), CA46-NCL-knockdown (KD), and CA46-NCL-KD control (KDC) cells were 0.68 +- 0.06 mug/ml, 0.68 +- 0.06 mug/ml, 0.68 +- 0.06 mug/ml, and 0.30 +- 0.04 mug/ml, respectively. Doxorubicin 0-10 nucleolin Homo sapiens 67-70 31127617-6 2019 Adriamycin (ADM) IC50 levels for CA46-NCL-overexpressed (OE), CA46-NCL-OE control (OEC), CA46-NCL-knockdown (KD), and CA46-NCL-KD control (KDC) cells were 0.68 +- 0.06 mug/ml, 0.68 +- 0.06 mug/ml, 0.68 +- 0.06 mug/ml, and 0.30 +- 0.04 mug/ml, respectively. Doxorubicin 0-10 nucleolin Homo sapiens 67-70 31127617-6 2019 Adriamycin (ADM) IC50 levels for CA46-NCL-overexpressed (OE), CA46-NCL-OE control (OEC), CA46-NCL-knockdown (KD), and CA46-NCL-KD control (KDC) cells were 0.68 +- 0.06 mug/ml, 0.68 +- 0.06 mug/ml, 0.68 +- 0.06 mug/ml, and 0.30 +- 0.04 mug/ml, respectively. Doxorubicin 0-10 nucleolin Homo sapiens 67-70 31127617-6 2019 Adriamycin (ADM) IC50 levels for CA46-NCL-overexpressed (OE), CA46-NCL-OE control (OEC), CA46-NCL-knockdown (KD), and CA46-NCL-KD control (KDC) cells were 0.68 +- 0.06 mug/ml, 0.68 +- 0.06 mug/ml, 0.68 +- 0.06 mug/ml, and 0.30 +- 0.04 mug/ml, respectively. Doxorubicin 12-15 nucleolin Homo sapiens 38-41 31127617-11 2019 Taken together, these results suggested that NCL could mediate Bcl-2 expression and stability, and thus enhance ADM resistance in CA46 BL cells. Doxorubicin 112-115 nucleolin Homo sapiens 45-48 31546295-9 2019 The results indicate that DOX-APTA12 conjugate is a potential option for chemotherapy especially for nucleolin expressing breast cancer with reduced doxorubicin associated side effects. Doxorubicin 26-29 nucleolin Homo sapiens 101-110 31202169-6 2019 In vitro studies showed that after the Lip(Ap-Dox) diffusing into MCF-7/Adr cells, Ap-Dox complex bound with nucleolin strongly and eventually entered the cell nuclei. Doxorubicin 46-49 nucleolin Homo sapiens 109-118 30172067-5 2018 Flow cytometry and confocal fluorescence microscopy revealed that PAMAM micelles with F3 attachment (PAMAM-DOX-F3) had stronger internalization into MDA-MB-231 cells (nucleolin-positive) than PAMAM micelles without F3 conjugation (PAMAM-DOX), whereas both of them have minimal interactions with L929 fibroblasts (nucleolin-negative). Doxorubicin 107-110 nucleolin Homo sapiens 167-176 30245388-5 2018 For relay drug delivery, imHDL/Apt-CpG-Dox underwent site-specific structure collapse in tumor intercellular substances inspired from HDL biofunctions (sequential module I); subsequently, dissociated Apt-CpG-Dox was endocytosed into tumor cells mediated by the recognition of AS1411 and nucleolin (sequential module II), translocating Dox to nucleus and enabling tumor ablation and antigens release. Doxorubicin 39-42 nucleolin Homo sapiens 287-296 30362711-7 2018 Finally, by translocation of nucleolin from cytoplasm to nucleus, the DS targets nucleus to delivery Dox. Doxorubicin 101-104 nucleolin Homo sapiens 29-38 31418358-1 2019 OBJECTIVE: To construct a K562 and adriamycin-resistant K562 (KAR) cell line with stably down-regulation of NCL (nucleolin) expression, and to investigate the effect of NCL down-regulation on the drug resistance in K562 and KAR cells. Doxorubicin 35-45 nucleolin Homo sapiens 108-111 31418358-1 2019 OBJECTIVE: To construct a K562 and adriamycin-resistant K562 (KAR) cell line with stably down-regulation of NCL (nucleolin) expression, and to investigate the effect of NCL down-regulation on the drug resistance in K562 and KAR cells. Doxorubicin 35-45 nucleolin Homo sapiens 113-122 31418358-5 2019 Compared with the control group, the proliferation of K562 and KAR cells with down-regulating NCL expression decreased significantly (P <0.05), the apoptosis of cells increased significantly (P <0.05), and cell resistance to adriamycin was down-regulated. Doxorubicin 231-241 nucleolin Homo sapiens 94-97 31418358-6 2019 CONCLUSION: Inhibition of NCL expression may increase the sensitivity of cells to adriamycin, which may be related with the promotion of apoptosis of K562 and KAR cells. Doxorubicin 82-92 nucleolin Homo sapiens 2-5 30320343-11 2019 Following stimulation with DOX, A549 cell proliferation and migration decreased and the expression of P-nucleolin also decreased. Doxorubicin 27-30 nucleolin Homo sapiens 104-113 30172067-5 2018 Flow cytometry and confocal fluorescence microscopy revealed that PAMAM micelles with F3 attachment (PAMAM-DOX-F3) had stronger internalization into MDA-MB-231 cells (nucleolin-positive) than PAMAM micelles without F3 conjugation (PAMAM-DOX), whereas both of them have minimal interactions with L929 fibroblasts (nucleolin-negative). Doxorubicin 107-110 nucleolin Homo sapiens 313-322 29902537-7 2018 Doxorubicin delivered by liposomes targeting nucleolin enabled a level of cytotoxicity that was 2.5- or 4.6-fold higher compared to the non-targeted counterparts. Doxorubicin 0-11 nucleolin Homo sapiens 45-54 30007600-2 2018 To provide the controlled, sustained drug release and enhance blood circulation, the surface of doxorubicin-encapsulated HMSNs were coated with acetylated carboxymethyl cellulose (Ac-CMC) and then covalently conjugated to AS1411 aptamer for guided drug delivery to nucleolin overexpressed cancerous cells. Doxorubicin 96-107 nucleolin Homo sapiens 265-274 26142627-5 2015 In this research, the cancer drug doxorubicin is encapsulated inside the gel during the formation of the hydrogel and then released in the presence of nucleolin. Doxorubicin 34-45 nucleolin Homo sapiens 151-160 28690315-9 2018 Moreover, combining nucleolin inhibitors: aptamer AS1411 or nucant N6L with doxorubicin reduced DLBCL cell survival. Doxorubicin 76-87 nucleolin Homo sapiens 20-29 28264987-5 2017 Upon doxorubicin treatment, the lncRNA SNHG1 is retained in the nucleus through its binding with nucleolin and it competes with p53 for hnRNPC binding, which upregulates p53 levels and promotes p53-dependent apoptosis by impairing hnRNPC regulation of p53 activity. Doxorubicin 5-16 nucleolin Homo sapiens 97-106 28690315-4 2018 Abrogation of nucleolin sensitized DLBCL cells to TopIIA targeting agents (doxorubicin/etoposide). Doxorubicin 75-86 nucleolin Homo sapiens 14-23 25305563-5 2014 In this work, we propose the active intracellular delivery of combinations of doxorubicin and the pro-apoptotic sphingolipid, C6-ceramide, using our previously described cytosolic triggered release-enabling liposomes, targeting nucleolin with the F3 peptide. Doxorubicin 78-89 nucleolin Homo sapiens 228-237